(Q33826469)

29 July 2017

1 reference

title

Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience (English)

1 reference

29 July 2017

Jardine A

1

1 reference

29 July 2017

Holdaas H

series ordinal

2

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Journal of Clinical Pharmacy and Therapeutics

29 July 2017

published in

1 reference

29 July 2017

volume

24

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

397-408

1 reference

Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Lipid abnormalities in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Dementia and Borna disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Treatment of hyperlipidemia in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

The adverse impact of cyclosporine on serum lipids in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Early graft function and patient survival following cadaveric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Efficacy and long-term adverse effect pattern of lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Cardiovascular complications after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00252.X

10.1046/J.1365-2710.1999.00252.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference